Literature DB >> 6166788

[Stage IIIB and IVB Hodgkin's disease. Response to chemotherapy, relapses, survival rates (author's transl)].

R Kuse, A Calavrezos, A Hinrichs, K Hausmann.   

Abstract

Thirty-two of 71 (45%) stage IIIB and IVB patients up to the age of 60 achieved a complete remission (CR) by initial COPP-chemotherapy. Twelve additional cases were free of symptoms after COPP, but showed persistent disease at postprimary laparotomy or within 3 months after cessation of chemotherapy. Forty-four per cent (n = 17) of this initial COPP failures could also be brought to CR by ABVD-chemotherapy or/and radiotherapy within 7 to 51 months. Cases with lymphocytic depletion reached CR in only 31% (N = 5/16) in comparison to 80% (n = 44/55) of the three other histological subtypes. Without additional consolidation therapy 60% relapsed, but only 11% after adjuvant total-nodal irradiation. An increase of side effects after therapy has not been observed so far. Patients with once attained CR have a survival probability of 93% after nearly 8 years from diagnosis. For the whole stage IIIB/IVB group the values were 85% up to the age of 30 (n = 28) and 60% for the age group of 31-60 (N = 43). They were clearly higher than in the 1966-1971 patients who showed values o 39% nd 41%, respectively. Beyond the stage of 60 (n = 15) the survival probability of 10% after 3 years in comparison to former 15% revealed no improvement.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166788     DOI: 10.1007/BF01721261

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

1.  The changing face of Hodgkin's disease.

Authors:  A C Aisenberg; R M Linggood; R A Lew
Journal:  Am J Med       Date:  1979-12       Impact factor: 4.965

2.  Long term remissions with combined modality therapy for advanced Hodgkin's disease.

Authors:  L R Prosnitz; L R Farber; J J Fischer; J R Bertino; D B Fischer
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

3.  [Polychemotherapy of Hodgkin's disease. Long-term results in 226 cases].

Authors:  C Jacquillat; G Auclerc; M F Gemon-Auclerc; M Weil; C Chastang; M Boiron; J Bernard
Journal:  Nouv Rev Fr Hematol Blood Cells       Date:  1977

4.  [Long term treatment of advanced vinblastine-resistant lymphogranulomatosis with ibenzmethyzin (Natulan)].

Authors:  E Schulz; H Cissée; K Hausmann
Journal:  Klin Wochenschr       Date:  1970-11-01

5.  Combination chemotherapy of Hodgkin's disease.

Authors:  D W Nison; A C Aisenberg
Journal:  Cancer       Date:  1974-06       Impact factor: 6.860

6.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

7.  Recent trends in the medical treatment of Hodgkin's disease.

Authors:  G Bonadonna; C Uslenghi; R Zucali
Journal:  Eur J Cancer       Date:  1975-04       Impact factor: 9.162

8.  [Prognostic factors concerning the survival time of Hodgkin's disease stage III and IV, treated with cytostatic agents].

Authors:  U Stoller; K Brunner
Journal:  Schweiz Med Wochenschr       Date:  1976-04-10

9.  New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.

Authors:  J J Lokich; E Frei; N Jaffe; J Tullis
Journal:  Cancer       Date:  1976-08       Impact factor: 6.860

10.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.

Authors:  V T DeVita; R M Simon; S M Hubbard; R C Young; C W Berard; J H Moxley; E Frei; P P Carbone; G P Canellos
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

View more
  1 in total

1.  Postchemotherapy staging laparotomy in Hodgkin's disease.

Authors:  R Kuse; A Calavrezos; K Hausmann
Journal:  Br J Cancer       Date:  1982-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.